MCT Index: Multiple Myeloma Trials List

2020

• NCT04688853: Phase 1 - A Study to Investigate the Safety and Efficacy of TEG002 in RRMM

• NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma

• NCT04674813: Phase 1 - A Study of CC-95266 in Subjects With Relapsed and/or Refractory Myeloma

• NCT04570631: Phase 1: Eftozanermin Alfa (ABBV-621) + Bortezomib and Oral Dexamethasone RRMM

• NCT04680468: Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant & Maintenance

• NCT04354246: Phase 1: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

• NCT04674514: Phase 1/2: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS RRMM Myeloma

• FDA Approved for RRMM: Xpovio (selinexor) tablets + Velcade (Bortezomib) and Dexamethasone

• NCT04635735: Phase 1/2: Study of Ipilimumab After Stem Cell Transplantation in People With RRMM

• NCT04634435: Phase 1/2: Auto Memory-like NK Cell + BHV-1100 (Formerly KP1237), Low Dose IL-2 in RRMM

• NCT04555551:Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma

• NCT04497961: Phase 2: A Study of Health-Related Quality of Life with Daratumumab or Lenalidomide

• NCT04505813: Phase 1- Antigen-specific T Cell Therapy NEXI 002 Relapsed Refractory Multiple Myeloma

• NCT04093596: Phase 1 - UNIVERSAL - ALLO-715 BCMA Allogenic CAR T Cells in relapsed Multiple Myeloma

• NCT04512235: Phase 3: CAEL-101 - To Evaluate Effectiveness & Safety of CAEL-101 in Stage IIIa AL Amyloidosis

• NCT04566328: Phase 3 - EQUATE Trial - EAA181 - Testing the Use of Combination Therapy in NDMM

• NCT04613557: Phase 1: IMMUNICY-1 - Safety, Activity and Cell Kinetics of CYAD-211 in RRMM Myeloma

• NCT04508790: Phase 2: Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of RRMM Myeloma

• IMPACT Study: The Immune Profiling with Antibody-based COVID-19 Testing - COVID-19 antibodies test

• NCT04545333: The clonoSEQ® Watch Registry

• NCT04287855: Phase 2: - IFM2018-03 - Phase 2 Study of Isatuximab + Pomalidomide, Dex, Carfilzomib RRMM

• NCT04521335: Phase 1: Repurpose-1 - Study of Disulfiram and Copper Gluconate in Patients With RRMM

• NCT04557098: Phase 2- MajesTEC-1 - Teclistamab, in Participants With Relapsed or Refractory Myeloma

• NCT04557150: Phase 1: Safety and Pharmacokinetics of Escalating Doses of RO7425781 RRMM Myeloma

• NCT04671251: Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

• NCT04564703: Phase 2: EMN26 - Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients - NDMM